ORIC’s research deal separates early spending from its later rights decision
By OnTheRice · Sources and limitations · Report a correction
Cancer Research UK will fund and run defined early work on ORIC-259. ORIC retains an option after Phase 1/2 data. That changes the stated spending burden while leaving clinical success and later economics open.
Source confidenceNot assessed
What’s changing?
Early spending and the rights decision occur at different stages. Future milestones and royalties remain part of the arrangement.
Key points
- Cancer Research UK will fund and run defined early work on ORIC-259.
- ORIC retains an option after Phase 1/2 data.
- That changes the stated spending burden while leaving clinical success and later economics open.
What could change this view?
- Funding cannot establish safety, efficacy or approval. The option may never be used; no cost or runway benefit is quantified.
Bottom line
More likely direction: BULLISH over the next 24 hours.
This is based on the information recorded with this signal.
How likely is this call? · Three frameworks
ORIC · BULLISH
Probability not recorded at publication. This earlier call is preserved without adding a hindsight estimate.
Evidence behind this view
Checks whether separate pieces of evidence support the same view.
Recorded connection
Early spending and the rights decision occur at different stages. Future milestones and royalties remain part of the arrangement.
We have not established a separate count of independent evidence clusters for this card. Several reports may rely on the same event or data provider.
What past price moves show
Compares today’s price moves with recorded past patterns.
No asset-specific historical pattern test is recorded separately for this card.
Evidence against this view
Shows evidence and risks that could challenge this view.
Recorded opposing evidence and risks
Funding cannot establish safety, efficacy or approval. The option may never be used; no cost or runway benefit is quantified.
Why the direction changed
Explains recorded changes from expecting a rise to expecting a fall, or the reverse.
No documented bullish-to-bearish or bearish-to-bullish change is available for this card. We keep the original call and its time unchanged.
What people say vs the facts
Compares recorded public discussion with checked market facts.
No separate Reddit or public-discussion comparison with verified market data is recorded for this card. We cannot treat social attention as proof of a market move.
How past forecasts performed
Shows recorded forecast results and what they can teach us.
Recorded outcomes for this signal: 0 HIT, 1 MISS, 0 other or pending. These counts are not a forecast probability.
No tested mapping from evidence combinations to future success is recorded for this card. Confidence in sources and past outcomes do not establish a calibrated probability.
Sources, original wording and price checks
Original research record
ORIC’s 5 October agreement assigns Cancer Research UK the funding and execution of trial-application studies and Phase 1/2 development. ORIC retains an exclusive option to reacquire rights afterward.
Early spending and the rights decision occur at different stages. Future milestones and royalties remain part of the arrangement.
OTR’s view: external funding preserves a later choice; an unexercised option is not commercial value already secured.
Nasdaq: ORIC is BULLISH / WATCH if funded development advances toward useful data on acceptable terms. Track studies and option disclosures; NO ENTRY.
Funding cannot establish safety, efficacy or approval. The option may never be used; no cost or runway benefit is quantified.
Stalled development, failed clinical evidence or unattractive terms weaken the case.
Study progress, trial registration and option economics; no completion date is stated.
Published
First published through Sites 06 Oct 2026, 12:18:23 SGT
24-hour check
- ORICBULLISH ✕ MISSPrice 1: 12.46500015 USD
At publication: 06 Oct 2026, 12:18:23 SGT
Price 2 (+24h): 11.98 USD
At +24h: 07 Oct 2026, 12:18:23 SGT
Change: -3.891%
Price 1 source: 06 Oct 2026, 03:59:00 SGT (offset -29963.693075 s)
Price 2 source: 07 Oct 2026, 04:00:00 SGT (offset -29903.693075 s)First published through Sites: 06 Oct 2026, 12:18:23 SGTCall and evidence
BULLISH / WATCH
The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.
Price series: ORIC · Nasdaq. Nearest available one-minute candle opening price to each fixed endpoint. Offsets are disclosed; original call and deadline are unchanged.
Price 1 · at publicationExact endpoint: 06 Oct 2026, 12:18:23 SGT
12.46500015 USD · Nearest intraday candle (approximation)
Source quote: 12.46500015 USD · 06 Oct 2026, 03:59:00 SGT
Source observation ↗Offset from required time: -29963.693075 seconds. Negative means before; positive means after.
One-minute candle start; candle opening price. This is an approximation to the requested instant.
Price 2 · exactly +24 hoursExact endpoint: 07 Oct 2026, 12:18:23 SGT
11.98 USD · Nearest intraday candle (approximation)
Source quote: 11.98 USD · 07 Oct 2026, 04:00:00 SGT
Source observation ↗Offset from required time: -29903.693075 seconds. Negative means before; positive means after.
One-minute candle start; candle opening price. This is an approximation to the requested instant.
Change: -0.48500015 USD (-3.891%). The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.
Correction: Owner-requested full recalculation using nearest available intraday prices and disclosed offsets; includes previously settled calls. The previous result remains in the immutable assessment history.
What changed
Recorded public historyCancer Research UK will fund and run defined early work on ORIC-259. ORIC retains an option after Phase 1/2 data. That changes the stated…
This is the first recorded public view. Further public updates will appear here.
- ORIC’s research deal separates early spending from its later rights decision
Cancer Research UK will fund and run defined early work on ORIC-259. ORIC retains an option after Phase 1/2 data. That changes the stated spending burden while leaving clinical success and later economics open.
First published by OTR: 6 Oct, 12:18 SGTPublished by OTR: 6 Oct 2026, 12:18 SGT
Why the view changed
This is the first recorded view. Future source-backed updates will appear here.
Evidence, memory & review 1 linked source
What changed: ORIC’s 5 October agreement assigns Cancer Research UK the funding and execution of trial-application studies and Phase 1/2 development. ORIC retains an exclusive option to reacquire rights afterward.
Named assets or actors: ORIC
Directional takeaway: BULLISH / WATCH / NO ENTRY
OTR reasoning: Early spending and the rights decision occur at different stages. Future milestones and royalties remain part of the arrangement.
Counterpoint: Funding cannot establish safety, efficacy or approval. The option may never be used; no cost or runway benefit is quantified.
Source trail
- ORIC Pharmaceuticals via GlobeNewswire ↗5 October 2026 16:01 ET = 20:01 UTC, minute precision · source clock as displayed
Review status: APPROVED
No score or probability is presented.